We won't get results published until 2023, much less commercialization. Missling misses every deadline. That's just a fact. By "around" I mean relevant. Plenty of companies that trade at or below cash.
BTW - I do think Anavex will fail in one the indications. Note that I have no basis for that statement except when you swing a bunch of fastballs you're going to likely miss one.
If that happens it's definitely over.
I 100% hope I'm wrong and not just because of the money, but mostly because how transformative a working drug for Alz and the other CNS diseases would be.